Management of proteinuria: blockade of the renin-angiotensin-aldosterone system

被引：5

作者：

Athavale, Ashkay ^{[1
]}

Roberts, Darren M. ^{[2
,3
]}

机构：

[1] Royal Prince Alfred Hosp, Drug Hlth Serv & Clin Pharmacol & Toxicol, Clin Pharmacol, Sydney, NSW, Australia

[2] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW, Australia

[3] St Vincents Hosp, Dept Renal Med & Transplantat, Sydney, NSW, Australia

来源：

AUSTRALIAN PRESCRIBER | 2020年 / 43卷 / 04期

关键词：

ACE inhibitors; albuminuria; angiotensin receptor antagonists; CHRONIC KIDNEY-DISEASE; DOUBLE-BLIND; RISK; SPIRONOLACTONE; OUTCOMES; HYPERKALEMIA; METAANALYSIS; ALBUMINURIA; NEPHROPATHY; INHIBITION;

D O I：

10.18773/austprescr.2020.021

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Proteinuria, in particular albuminuria, is a potentially significant modifiable risk factor for cardiovascular disease and the progression of kidney disease. Current treatment guidelines for albuminuria recommend a single renin-angiotensin-aldosterone inhibitor. This can be an ACE inhibitor or an angiotensin receptor antagonist. The routine use of combined renin-angiotensin-aldosterone inhibition for albuminuria is not supported by current evidence. Combination therapy is associated with higher rates of adverse events such as hyperkalaemia and progressive renal impairment.

引用

页码：121 / 125

页数：5

共 36 条

[1] Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort [J].

Abbas, Sascha ;

Ihle, Peter ;

Harder, Sebastian ;

Schubert, Ingrid .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (04) :406-413

[2] How does proteinuria cause progressive renal damage? [J].

Abbate, Mauro ;

Zoja, Carla ;

Remuzzi, Giuseppe .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (11) :2974-2984

[3] ONTARGET should not be over interpreted [J].

Abutaleb, Nasrulla .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (01) :44-47

[4]

[Anonymous], 2014, CHRON KIDN DIS AD AS

[5]

[Anonymous], 2015, CHRONIC KIDNEY DIS C

[6]

[Anonymous], N ENGL J MED

[7]

[Anonymous], 2013, KDIGO 2012 CLIN PRAC, DOI DOI 10.1038/KISUP.2012.64

[8] Slowing nephropathy progression: Focus on proteinuria reduction [J].

Bakris, George L. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 :S3-S10

[9] Aldosterone antagonists for preventing the progression of chronic kidney disease [J].

Bolignano, Davide ;

Palmer, Suetonia C. ;

Navaneethan, Sankar D. ;

Strippoli, Giovanni F. M. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04)

[10] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

← 1 2 3 4 →